Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: swoboda4 who wrote (312)	12/22/1997 9:47:00 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 675

My comments were not a statement regarding CNSI's intrinsic worth: the market is not valuing them rationally, though I would be hard-pressed to think of more than a handful of companies in the neuro sector that are being valued rationally. The price may be a bargain, but the Market is going to take a while to adjust to the shift, from looking at CNSI the company that has Cerestat about-to-emerge, to CNSI the early-stage R&D company that has just started human trials with 5161, without punishing them for it. In other words, if CNSI had this much cash, plus its discovery programs, and Cerestat had never existed, CNSI would be selling at a somewhat higher price than is currently the case. NeuroInvestment